Articles

Harmonization of Clinical Trial Regulations: PMDA, TGA & CDSCO Compared

This article compares the clinical trial regulations of PMDA, TGA, and CDSCO, focusing on their impact on drug development and patient safety.

Purdue Pharma Shutdown: $7.4B Deal Ends OxyContin Maker's Era

Purdue Pharma, the manufacturer of OxyContin, is ceasing operations as part of a $7.4 billion settlement to resolve claims related to the opioid crisis. This landmark deal signifies a major turning point in the legal and societal reckoning with the epidemic.

NMPA Accelerated Approval Pathway: Impact on Innovative Drug Market Entry in China

The NMPA Accelerated Approval Pathway significantly enhances the speed of innovative drug market entry in China, particularly for critical cancer treatments.

NMPA Approval Lung Cancer Immunotherapy: PD-1/PD-L1 Combo Trends 2025

This article delves into the NMPA's approval landscape for lung cancer immunotherapy, highlighting the emerging trends of PD-1/PD-L1 combination therapies by 2025.

NMPA Conditional Approval Pathway: Impact on Innovative Oncology Drug Access

The NMPA Conditional Approval Pathway significantly enhances access to innovative oncology drugs, facilitating timely treatment options for cancer patients.

African Medicines Agency Implementation: Transforming Regulatory Harmonization & Market Access

The African Medicines Agency is set to revolutionize regulatory processes, ensuring faster market access for vital medicines across the continent.

NMPA Priority Review Pathway: Accelerating Innovative Drug Approvals in China

The NMPA Priority Review Pathway accelerates the approval of innovative drugs in China, significantly benefiting patients with critical health needs.

NMPA Data Integrity Requirements: What Foreign Pharma Must Know in APAC

Understanding NMPA data integrity requirements is essential for foreign pharmaceutical companies aiming to navigate drug registration in the APAC region.

Biosimilar Regulation Japan: Aligning PMDA with EMA and FDA Guidelines

This article examines Japan's biosimilar regulations, focusing on how the PMDA aligns with EMA and FDA guidelines to enhance the approval process for drugs like infliximab.

NMPA Foreign Clinical Trial Data: What You Need to Know

This article explores the significance of NMPA foreign clinical trial data for drug approvals, focusing on its impact on cancer therapies and regulatory compliance.

NMPA Data Integrity Requirements: What Foreign Pharma Must Know in APAC

Understanding NMPA data integrity requirements is crucial for foreign pharmaceutical companies seeking to navigate the APAC market effectively.

Biosimilar Market in Japan: Growth Trends Post-PMDA Guideline Revisions

The biosimilar market in Japan is experiencing significant growth following PMDA guideline revisions, impacting drugs such as adalimumab for rheumatoid arthritis.

NMPA Data Integrity Compliance: What Foreign Pharma Must Know in APAC

Navigating NMPA data integrity compliance is crucial for foreign pharmaceutical companies in APAC. Discover essential guidelines for successful drug registration.

China Clinical Trial Regulations: Key Insights on NMPA Reforms 2024

Discover key insights on the 2024 NMPA reforms in China, shaping clinical trial regulations and their implications for drug development in oncology and rare diseases.

Clinical Trial Quality Management Systems: New APAC Standards & Challenges

This article delves into the latest APAC standards for clinical trial quality management systems, highlighting challenges in ensuring drug efficacy and patient safety.

China NMPA Data Integrity: What Foreign Pharma Must Know for Approval

Understanding China NMPA data integrity is crucial for foreign pharmaceutical companies seeking approval for their drugs in the competitive Chinese market.

Biosimilar Landscape Japan: PMDA Regulatory Updates & Market Access 2024

Stay informed on Japan's biosimilar landscape with the latest PMDA regulatory updates and market access strategies for 2024, focusing on critical therapies like Adalimumab.

Biosimilars in Japan: Market Growth and PMDA Regulatory Insights 2024

This article delves into the expanding biosimilars market in Japan, focusing on trastuzumab's role in cancer treatment and the latest PMDA regulatory updates for 2024.

Pfizer AI Strategy: Driving Pharma Innovation and Dominance

Discover how Pfizer’s AI strategy is transforming pharmaceutical R&D, accelerating drug discovery, optimizing clinical trials, and reinforcing its leadership in the pharma industry, with a focus on the APAC region.

AI Drug Discovery Patent Rankings 2025: Deep EigenMatics Leads Globally

Deep EigenMatics has topped the 2025 AI drug discovery patent rankings, outpacing major pharma globally. Discover how AI is reshaping pharmaceutical innovation.